医铭康达(北京)生物医药有限公司于2022 年8 月成立,由清华大学讲席教授、昌平实验室教授傅阳心教授转化、由产业资深专家傅道田博士共同创立。主要从事新一代基于免疫治疗的生物创新药的研发,旨在突破肿瘤、自免和治疗性疫苗的免疫治疗现有瓶颈。医铭康达以源头创新为核心、以免疫治疗为基础、以临床价值为导向,充分结合前沿科学创新和产业转化的能力,促进产学研充分合作并实现创新的高效转化,来打造新一代免疫驱动的创新生物药研发公司。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows